In 2016, the World Health Organization (WHO) classification of myeloproliferative neoplasms specifically recognized the JAK2 V617F mutation as one of the main diagnostic criteria of Philadelphia-negative MPNs [8]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.